Australia's largest stock trading and investment forum Australia's #1 stock forum

MSB

1.03%

98.0¢ mesoblast limited

Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-484

First 484 Last

Share
Profile

Follow
dnyland

3,703 Posts.

48

13/01/21

13:53

Post #: 50139517
Share

Originally posted by stanjupiter: ↑

Note the spooks that have operated on this forum for years training us to reason through association. GvHD, ARDS, CHF trials are all different and conducted in different context.

I think it's important to try to look at the thing itself and nothing else and its context. A lot is just common sense and something most of us have.

There are posters posing as sceptics whose purpose imo is to generate scepticism. A WaPO (Bezos) article got posted here as a 'respected' source (ROFL) Note WaPo's respect for 'fact checking' website Snopes, which uses a similar tactic to the one certain posters use on here of constructing an argument and leaving out a crucial piece of information.

The article's behind a paywall but I recall it well; it was 'debunking' stem cells for the heart and caused a bit of stir on here. Its readership is educated, so presumably it knew there was nothing to debunk; there's been a lot of failure in stem cells for heart and widespread scepticism.

Perhaps for this reason, MSB's trial went for a conservative primary end point, not thinking such results could be possible? Now some posters are telling us with authority that FDA might not approve because of missing primary end point. The FDA being 'sceptical' might require a further trial to confirm these stunning and unexpected results?

Sounds to me a bit like Catch 22 as in ARDS trial.

Following the narrative in the media, after 25 years of debate on steroids and ARDS in top journals, it was only during this pandemic that doctors worked out how best to use them? A directive from the WHO to use steroids in Covid ARDS, backed up by the spook machine the BBC that told us if DEX had been used in the beginning 5000 patients could have been saved.

I don't see how this couldn't have affected the ARDS trial. Our cells respond to signals of inflammation. My view is the gap between treatment and placebo narrowed because both arms became DEX.

I still think ARDS might still be in with a chance if there's enough data from the first half of the trial. A brief reading of the literature told me that most ARDS patients survive, but many survive badly. That's what insurers are paying hugely for and I've written in great detail about, tried to find recent sources.

I think the situation in ARDS is as bad as it ever was. I hope Novartis will have the common sense to run a trial against steroids.

All IMO

Expand

'There are posters posing as sceptics whose purpose imo is to generate scepticism. A WaPO (Bezos) article got posted here as a 'respected' source (ROFL) Note WaPo's respect for 'fact checking' website Snopes, which uses a similar tactic to the one certain posters use on here of constructing an argument and leaving out a crucial piece of information.'

I wasn't aware of Bezos owning WaPo. I have seen some of their Headline stories which were later shown to be BS. Keen to know more about WaPo fact checking with regard to MSB. Anyone.

MSB Price at posting: $2.45 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

ASX200 dives as inflation clocks in at 4% – higher than 3.8% consensus

NIM

Nimy extends sulphide targets at Mons with new anomalies identified

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

SFX

Sheffield Resources achieves milestone production, shipments at Thunderbird, WA

NXM

Drilling at Bethanga shows signs of Cu-Au porphyry system for Nexus

There are more pages in this discussion • 280 more messages in this thread...

First 484 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 98.0¢		Change 0.010(1.03%)		Mkt cap ! $1.118B

Open	High	Low	Value	Volume
96.0¢	99.0¢	95.5¢	$5.286M	5.409M

Buyers (Bids)

No.	Vol.	Price($)
3	91218	98.0¢

Sellers (Offers)

Price($)	Vol.	No.
99.0¢	63577	4

View Market Depth

No.	Vol.	Price($)
3	91218	0.980
42	307626	0.975
14	519246	0.970
6	149303	0.965
8	166210	0.960

Price($)	Vol.	No.
0.990	63577	4
0.995	68052	2
1.000	121535	11
1.005	55374	2
1.010	10000	1

Last trade - 16.10pm 27/06/2024 (20 minute delay)

MSB (ASX) Chart

Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-484

ASX200 dives as inflation clocks in at 4% – higher than 3.8% consensus

Nimy extends sulphide targets at Mons with new anomalies identified

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Sheffield Resources achieves milestone production, shipments at Thunderbird, WA

Drilling at Bethanga shows signs of Cu-Au porphyry system for Nexus

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-484

Top Stories

ASX200 dives as inflation clocks in at 4% – higher than 3.8% consensus

Nimy extends sulphide targets at Mons with new anomalies identified

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Sheffield Resources achieves milestone production, shipments at Thunderbird, WA

Drilling at Bethanga shows signs of Cu-Au porphyry system for Nexus

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News